

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SUPPLEMENTARY TABLES

Table S1. Number of persons treated with biologics by year among 10,302 incident patients with Crohn’s disease (CD) and 22,144 incident patients with ulcerative colitis (UC) in Denmark, 2003-2016

	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	Total
CD patients treated with biologics	0	7	32	90	248	399	566	777	923	1,121	1,260	1,447	1,571	1,680	2,939
Incident CD population, cumulated	771	1,582	2,368	3,090	3,839	4,601	5,328	6,162	6,985	7,760	8,464	9,148	9,646		10,302
% of incident CD patients treated with biologics	0%	0%	1%	3%	6%	9%	11%	13%	13%	14%	15%	16%	16%		29%
UC patients treated with biologics	0	<5	5	38	113	174	258	353	482	603	699	890	986	1,020	2,504
Incident UC population, cumulated	1,681	3,429	5,114	6,713	8,258	9,919	11,748	13,519	15,401	16,883	18,244	19,437	20,321		22,144
% of incident UC patients treated with biologics	0%	-	0%	1%	1%	2%	2%	3%	3%	4%	4%	5%	5%		11%

Note: The share is calculated as share of cumulated incident patients alive primo in the given year. A person is included if they receive biologic treatment in the given calendar year. The total shows the share of the patient populations incident in 2003-2015 who received treatment with biologics at any point during the study period 2003-2016.

Table S2. Number of patients initiating biologic treatment each year among 10,302 incident patients with Crohn's disease (CD) and 22,144 incident patients with ulcerative colitis (UC) in Denmark, 2003-2016

	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	2016	Total
CD patients initiating biologic treatment	0	7	27	73	202	209	248	308	296	329	300	357	369	214	2,939
Incident CD population, cumulated	771	1,582	2,368	3,090	3,839	4,601	5,328	6,162	6,985	7,760	8,464	9,148	9,646		10,302
% of incident CD patients initiating biologics	0%	0%	1%	2%	5%	5%	5%	5%	4%	4%	4%	4%	4%		29%
UC patients initiating biologic treatment	0	<5	<5	37	101	123	177	222	274	277	300	382	371	235	2,504
Incident UC population, cumulated	1,681	3,429	5,114	6,713	8,258	9,919	11,748	13,519	15,401	16,883	18,244	19,437	20,321		22,144
% of incident UC patients initiating biologics	0%	-	-	1%	1%	1%	2%	2%	2%	2%	2%	2%	2%		11%

Note: The population includes incident patients with CD or UC. A person is counted if they initiated biologic treatment in the given calendar year, but after their IBD diagnosis.

Table S3. Time from diagnosis to first treatment with biologics among 2,939 incident patients with Crohn's disease (CD) and 2,504 incident patients with ulcerative colitis (UC) in Denmark treated with biologics in 2003-2016.

	Within 1 year	1-2 years	2-3 years	3-4 years	4-5 years	5-6 years	6-7 years	7-8 years	8-9 years	9-10 years	10+ years	Total
Number of CD patients	1,358	479	261	201	172	122	97	77	58	44	70	2,939
% of CD patients	46%	16%	9%	7%	6%	4%	3%	3%	2%	1%	2%	100%
Number of UC patients	1,132	387	228	176	166	117	73	66	60	33	66	2,504
% of UC patients	45%	15%	9%	7%	7%	5%	3%	3%	2%	1%	3%	100%

Note: The population includes incident patients with CD or UC who initiated biologic treatment.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1 Table S4. Months between last treatment in treatment line one and first treatment in treatment line
2 two among 1,017 incident patients with Crohn’s disease (CD) and 581 incident patients with
3 ulcerative colitis (UC) in Denmark treated with more than 1 biologic therapy in 2003-2016.

Months	CD patients	UC patients	CD, cumulative	UC, cumulative
[0-1[32.4%	34.4%	32.4%	34.4%
[1-2[24.4%	33.7%	56.7%	68.2%
[2-3[9.1%	9.1%	65.9%	77.3%
[3-4[6.6%	3.3%	72.5%	80.5%
[4-5[3.5%	1.9%	76.0%	82.4%
[5-6[3.2%	2.9%	79.3%	85.4%
[6-7[1.8%	1.0%	81.0%	86.4%
[7-8[1.0%	1.4%	82.0%	87.8%
[8-9[1.1%	0.5%	83.1%	88.3%
[9-10[1.8%	1.2%	84.9%	89.5%
[10-11[1.4%	0.9%	86.2%	90.4%
[11-12[0.8%	1.0%	87.0%	91.4%
12 or more	13.0%	8.6%	100.0%	100.0%
Total	100.0%	100.0%		

4 Note: The population includes incident patients with CD or UC who received treatment with more than one biologic
5 therapy.